ISARIC Clinical Data Report issued: 14 July 2021
Baillie JK., Baruch J., Beane A., Blumberg L., Bozza F., Broadley T., Burrell A., Carson G., Citarella B., Dagens A., Dunning J., Elotmani L., Escher M., Farshait N., Garcia Barrio N., Goffard J-C., Hall M., Hashmi M., Horby P., Ignacio M-L., Jassat W., Jayakumar D., Kartsonaki C., Kumar Vecham P., Laouenan C., Mentre F., Morton B., Munblit D., Nekliudov NA., Nichol AD., Oinam BS., Ong D., Panda PK., Kumar Tirupakuzhi Vijayaraghavan B., Lissauer S., Pedrera Jimenez M., Petrovic M., Ramakrishnan N., Roger C., Rojek A., Sandulescu O., Sharma P., Somers EC., Streinu-Cercel A., Taccone F., Ramos GV., Semple MG., Sim Lim Heng B., Wei J., Wils E-J., Wong XC., Olliaro PL., Merson L.
AbstractISARIC (International Severe Acute Respiratory and emerging Infections Consortium) partnerships and outbreak preparedness initiatives enabled the rapid launch of standardised clinical data collection on COVID-19 in Jan 2020. Extensive global uptake of this resource has resulted in a large, standardised collection of comprehensive clinical data from hundreds of sites across dozens of countries. Data are analysed regularly and reported publicly to inform patient care and public health response. This report, our 15th report, is a part of a series and includes the results of data analysis for data captured before 26 May 2021. The report marks a significant milestone – the submission of clinical data from over half a million individuals hospitalised with COVID-19. We thank all of the data contributors for their ongoing support.Data have been entered for 516,689 individuals from 788 partner institutions and networks, covering more than 1600 sites across 61 countries. This is a significant increase in data volumes and contributing countries since our most recent report dated 08 April 2021.The comprehensive analyses detailed in this report includes hospitalised individuals of all ages: for whom data collection occurred between 30 January 2020 and up to and including 25 May 2021; ANDwho have laboratory-confirmed SARS-COV-2 infection or clinically diagnosed COVID-19.For the 442,643 cases who meet eligibility criteria for this report, selected findings include: median age of 60 years, with an approximately equal (50/50) male:female sex distributionone third of the cohort are at least 70 years of age, whereas 3% are 0-19 years of agethe most common symptom combination in this hospitalised cohort is shortness of breath, cough, and history of fever, which has remained constant over timethe five most common symptoms at admission were shortness of breath, cough, history of fever, fatigue/malaise, and altered consciousness/confusion, which is unchanged from the previous reportsage-associated differences in symptoms are evident, including the frequency of altered consciousness increasing with age, and fever, respiratory and constitutional symptoms being present mostly in those 40 years and above16% of patients with relevant data available were admitted at some point during their illness into an intensive care unit (ICU), which is slightly lower than previously reported (19%)antibiotic use remains very high (61%), although it is lower than previously reported (80%), in those for whom relevant data are available (288,125); in ICU/HDU patients with data available (36,073), 92% received antibioticsuse of corticosteroids was reported for 25% of patients of all types for whom data were available (288,125); in ICU/HDU patients with data available (36,021), 62% received corticosteroidsoutcomes are known for 411,368 patients and the overall estimated case fatality ratio (CFR) is 25% (95%CI 24.8-25), rising to 38% (95%CI 37.5-38.3) for patients who were admitted to ICU/HDU, demonstrating worse outcomes in those with the most severe disease To access previous versions of ISARIC COVID-19 Clinical Data Report please use the link below: https://isaric.org/research/covid-19-clinical-research-resources/evidence-reports/